Ge Xiaoxia — Intellectual Property Lawyer in Suzhou

This combination is particularly relevant in Suzhou, where many companies preparing for capital-market transactions derive a large part of enterprise value from patents, technical know-how, software, medical-device technology or R&D personnel. For such issuers, intellectual property is not merely an appendix to the prospectus. It affects business independence, core technology, related-party transactions, ownership disputes and continuity of operations.

Ge's representative work includes IPO projects involving water services, medical technology, heavy industry and technology businesses, as well as financing transactions for biomedical and medical-device companies. This sector range matters because legal issues in an IPO depend heavily on the issuer's business model. A technology issuer needs strong evidence of IP ownership and R&D independence; a manufacturing issuer may need clarity on land, equipment and technology licenses; a healthcare company may need to integrate regulatory licenses with IP and commercial rights.

Her profile also lists ongoing counsel to research institutions and technology companies. This is relevant because technology commercialization often begins with relationships among research institutes, founders, universities, employees and investors. Before an IPO, the company may need to clarify who owns patents developed before incorporation, whether employee inventors were properly compensated, whether technology licenses are exclusive, and whether related parties retain rights that undermine the issuer's independence.

Under China's registration-based IPO framework, an issuer must satisfy conditions relating to lawful establishment, corporate governance, accounting, internal control and ability to operate independently. The CSRC's IPO registration rules and exchange requirements place significant emphasis on truthful, accurate and complete disclosure. For a technology issuer, unresolved IP ownership or major litigation can become a listing issue because investors need to understand whether the company controls its core assets.

Ge's patent-agent qualification helps bridge legal and technical diligence. Patent registers alone do not establish that a company owns all commercially necessary technology. Counsel may need to review employee invention arrangements, assignment agreements, license restrictions, co-ownership, pledge, disputes and technology developed with universities or government-funded institutes.

For foreign investors in Suzhou technology companies, these same issues arise in pre-IPO financing. An investor may rely on a future listing as an exit route, so IP defects discovered by the exchange or regulator can reduce valuation or delay exit. Good pre-IPO legal work therefore starts years before the filing.

Her capital-markets work also intersects with equity financing. A company raising a Series C or D round before IPO may grant investor rights that later need to be cleaned up before listing. Redemption rights, special voting arrangements, preferential distributions or nominee arrangements may need review. The legal team should therefore design private-round documents with the future listing path in mind.